Proudly Based in Canada | Premium Research Peptides for Modern Science
Free Shipping on Orders Over $300 CAD
Every cell needs energy, but energy is not made in empty space.
Inside the cell, mitochondria are often described as powerhouses. The phrase is useful, but it is too simple. A mitochondrion is not just a battery floating in the cytoplasm. It is a folded, membrane-built machine. Its inner membrane bends into cristae, creating an intricate landscape where electrons move, oxygen is used, ATP is produced, and the cell’s energy economy is maintained.
That folded membrane is one of the most important surfaces in biology.
It is here, along the inner mitochondrial membrane, that the electron transport chain works. It is here that fuel becomes usable energy. It is here that life depends on structure. If the membrane is organized, the machinery can run efficiently. If the membrane becomes damaged, distorted, or unstable, the system begins to falter. Energy production weakens. Reactive oxygen species can rise. Cellular stress increases. Tissues with the highest energy demands — heart, muscle, brain, retina, kidney — are often the first to feel the consequences.
SS-31 was born from an unusually direct idea: what if a small peptide could reach that membrane?
Most compounds do not easily reach the inner mitochondrial membrane. The cell is protected by barriers, and the mitochondrion has barriers of its own. The inner membrane is not an easy destination. Yet SS-31, later known as elamipretide, was designed as part of a family of small, cell-permeable peptides that could move into cells and associate with mitochondria. It was only four amino acids long, but its destination made it extraordinary.
Its sequence — D-Arg–Dmt–Lys–Phe-NH₂ — looks modest on paper. Four amino acids. A synthetic tetrapeptide. But biology is full of small structures that become powerful because of where they go. SS-31 did not need to be large to matter. Its importance came from its ability to reach one of the most energy-critical places in the cell.
At first, SS-31 was often described as a mitochondria-targeted antioxidant. That made sense. Mitochondria are major sources of reactive oxygen species, especially under stress, and early research showed that SS-31 could reduce mitochondrial injury in models of oxidative stress and ischemia-reperfusion damage. But over time, the story became more specific and more interesting.
The key was cardiolipin.
Cardiolipin is a specialized lipid found mainly in the inner mitochondrial membrane. It helps shape mitochondrial cristae and supports the organization of the electron transport chain. In other words, cardiolipin helps hold the power grid together. When cardiolipin is damaged or poorly remodeled, the architecture of energy production begins to suffer. SS-31 became important because it appeared to interact with cardiolipin-rich membrane environments, helping stabilize the structure where mitochondrial energy production depends on order.
That changed the way researchers thought about the peptide.
SS-31 was not simply a molecule that cleaned up damage after it happened. It was a peptide aimed at the place where mitochondrial damage and energy failure begin: the inner membrane itself. Its story moved from antioxidant protection to membrane stabilization, from reactive oxygen species to cardiolipin biology, from generic “mitochondrial support” to something much more precise — protecting the architecture that makes energy possible.
This made SS-31 scientifically attractive across many fields. Mitochondrial dysfunction appears in heart failure, muscle disease, kidney injury, retinal degeneration, ischemia-reperfusion injury, and rare genetic disorders. Wherever energy demand is high and mitochondrial stress is severe, researchers wondered whether protecting the inner membrane could make a difference.
The answer was not simple.
Some clinical trials were disappointing. In primary mitochondrial myopathy, elamipretide did not meet its primary endpoints in a broad, genetically diverse patient population. In heart failure, results did not deliver the clear functional improvement researchers had hoped for. These failures matter. They show that mitochondrial medicine is not as simple as finding one molecule that “boosts energy.” Mitochondrial disease is not one disease. Energy failure can come from many different genetic, structural, and metabolic causes.
But one disease brought SS-31’s story into sharp focus.
Barth syndrome is a rare, serious mitochondrial disease linked to defective cardiolipin remodeling. In Barth syndrome, the very lipid architecture that SS-31 was designed to support is part of the disease’s core biology. That made the match unusually meaningful. A peptide that interacted with cardiolipin-rich mitochondrial membranes was being tested in a disorder where cardiolipin biology was broken.
This is where SS-31 became more than a research tool.
As elamipretide, and later under the approved name Forzinity, SS-31 entered one of the most emotionally charged areas of modern medicine: ultra-rare disease. The path was difficult. Regulators debated the strength of evidence. Patient families pushed for access. Scientists wrestled with endpoints, small trial sizes, and what counts as enough proof when the disease population is tiny and the need is urgent. In 2025, Forzinity received accelerated approval as the first treatment for Barth syndrome in eligible patients, turning SS-31 into a landmark story in mitochondrial medicine.
The story of SS-31 is therefore not only about energy.
It is about structure. It is about the fragile architecture of the inner mitochondrial membrane. It is about cardiolipin, cristae, electron flow, oxidative stress, rare disease, trial failure, regulatory debate, and the difficult road from elegant mechanism to real medicine.
Most of all, it is about a small peptide that tried to reach the cell’s engine room.
Not to force the cell to do more.
But to help protect the membrane where energy itself is made.
Mitochondrial failure rarely looks like one single problem.
It can look like muscle weakness. It can look like fatigue that rest does not fully repair. It can appear in the heart, where every beat depends on enormous energy demand. It can appear in the retina, where light-sensing cells require constant metabolic support. It can appear in the kidney, the brain, the liver, or any tissue where cellular work depends on a steady supply of ATP.
That is what makes mitochondrial medicine so difficult.
The mitochondrion is not just an energy source. It is a control center for metabolism, stress response, calcium handling, reactive oxygen species, and cell survival. When mitochondria begin to fail, the consequences spread outward. Energy production drops. Oxidative stress rises. The cell’s ability to manage damage weakens. Signals that should stay balanced become distorted. In tissues that live near the edge of high energy demand, even small losses in mitochondrial efficiency can become meaningful.
But the problem is deeper than low energy.
The inner mitochondrial membrane is where energy production is organized. This membrane folds into cristae, creating the structure needed for the electron transport chain to work efficiently. Along this folded surface, electrons pass through protein complexes, protons are pumped, and ATP synthase uses the resulting gradient to produce ATP. The structure matters because the machinery depends on arrangement. Energy is not made by loose parts floating randomly. It is made by ordered systems held in place by membrane architecture.
Cardiolipin is one of the key molecules that helps maintain that architecture.
This unusual lipid is concentrated in the inner mitochondrial membrane. It supports the shape of cristae and helps organize the protein complexes involved in oxidative phosphorylation. It is also vulnerable. Under stress, cardiolipin can become oxidized, damaged, or improperly remodeled. When that happens, the membrane environment changes. The electron transport chain can become less efficient. Electron leak can increase. Reactive oxygen species can rise. The mitochondrion’s power grid begins to lose its order.
This is where mitochondrial dysfunction becomes more than a chemistry problem.
It becomes an architecture problem.
A power grid does not fail only because it runs out of fuel. It can fail because the wires are damaged, the connections are unstable, the structure is overloaded, or the system can no longer move energy cleanly from one place to another. In the same way, mitochondria can struggle not only because the cell lacks fuel, but because the membrane environment that organizes energy production has been disrupted.
For years, one of the major hopes in mitochondrial medicine was antioxidant therapy. The logic made sense: mitochondrial stress often produces reactive oxygen species, so reducing oxidative damage might protect the cell. But broad antioxidant approaches have often disappointed because oxidative stress is not always the root cause. Sometimes it is a symptom of a deeper structural failure. If the membrane is disorganized and electron flow is inefficient, then simply cleaning up reactive oxygen species after the fact may not be enough.
SS-31 entered this problem from a different angle.
Instead of acting only as a general antioxidant, SS-31 was designed to reach mitochondria and associate with the inner mitochondrial membrane. That made the peptide interesting because it aimed closer to the source of the problem. If cardiolipin-rich membrane environments were central to mitochondrial structure and energy production, then a peptide capable of interacting with that environment might help stabilize the system before the damage spread.
The most powerful disease example is Barth syndrome.
Barth syndrome is rare, serious, and rooted in mitochondrial biology. It is linked to defects in tafazzin, a protein involved in cardiolipin remodeling. When cardiolipin remodeling is impaired, mitochondria cannot maintain their normal lipid architecture as effectively. This can affect heart muscle, skeletal muscle, growth, endurance, and overall energy metabolism. For families living with Barth syndrome, mitochondrial dysfunction is not an abstract concept. It is part of daily life.
This made Barth syndrome a uniquely meaningful test for elamipretide.
If SS-31’s deeper story was cardiolipin and inner membrane stabilization, then Barth syndrome offered a disease where cardiolipin biology was not peripheral — it was central. The match between mechanism and disease was unusually clear. A peptide designed to protect cardiolipin-rich mitochondrial membranes was being studied in a condition where cardiolipin remodeling itself was broken.
But even here, the problem remained difficult.
Rare diseases create scientific challenges that large diseases do not. Patient populations are small. Trials are hard to design. Endpoints can be debated. Functional changes may matter deeply to patients but be difficult to measure cleanly in conventional clinical terms. A therapy can appear promising, yet still leave regulators asking whether the evidence is strong enough. In mitochondrial disease, where symptoms can vary widely and progression may be uneven, the challenge becomes even harder.
That is why SS-31’s story cannot be told as a simple triumph of mitochondrial support.
The peptide entered a field where the need was enormous, the biology was compelling, and the evidence standards were difficult to satisfy. It was studied across multiple conditions because mitochondrial dysfunction appears in many diseases. But not every disease responded the same way. Some trials missed their endpoints. Some findings were encouraging but not definitive. Some applications remained preclinical. The problem was not that the mitochondrial idea was wrong. The problem was that mitochondrial failure has many faces.
This is the central tension of SS-31.
If the inner mitochondrial membrane is the cell’s power grid, then protecting that grid should matter. But medicine must still prove where, when, and for whom that protection changes outcomes. A peptide can have an elegant mechanism and still face difficult clinical translation. A disease can have a desperate need and still require careful evidence. A biological target can be real without becoming a universal solution.
The power grid can fail in many ways.
SS-31 became important because it tried to protect one of the places where failure begins: the folded, cardiolipin-rich membrane where energy is made. Its promise came from that precision. Its challenge came from the complexity of the diseases it hoped to treat.
The problem was not just damaged mitochondria.
The problem was learning whether a tiny peptide could protect the architecture of energy itself — and whether that protection could become meaningful in the lives of people whose cells were running out of power.
The discovery of SS-31 was not only the discovery of a peptide.
It was the discovery of a destination.
In biology, where a molecule goes can be just as important as what it is. A compound may look promising in a test tube, but if it cannot reach the right compartment inside the cell, its potential can disappear. The cell is full of barriers. Membranes divide one space from another. Organelles protect their internal machinery. Mitochondria, with their outer and inner membranes, are especially difficult targets.
This is what made the Szeto–Schiller peptides unusual.
Hazel H. Szeto and Peter W. Schiller worked at the intersection of pharmacology and peptide chemistry. Their collaboration produced a family of small synthetic peptides that were able to enter cells and associate with mitochondria. The name SS came from their names: Szeto–Schiller. It was a fitting name for a peptide family built from two complementary scientific strengths — one focused on biological function and mitochondrial protection, the other on the chemical design of peptides.
SS-31 emerged from this family as a tiny but remarkable molecule.
Its structure was simple enough to remember: D-Arg–Dmt–Lys–Phe-NH₂. Four amino acids. One of them, Dmt, is 2’,6’-dimethyltyrosine, an aromatic residue that helped give the peptide its distinctive chemical behavior. The structure alternated charged and aromatic features, allowing it to move through biological environments and interact with mitochondrial membranes in a way that ordinary peptides often could not.
That was the first breakthrough.
SS-31 could enter cells.
The second breakthrough was more important.
SS-31 could reach mitochondria.
Early research described the Szeto–Schiller peptides as cell-permeable, mitochondria-targeted peptide antioxidants. In foundational work, researchers showed that these peptides could localize to mitochondria and protect against mitochondrial swelling, oxidative cell death, and ischemia-reperfusion injury. For SS-31, this meant the peptide was not simply floating around the cell as a general protective molecule. It was going to the place where mitochondrial stress was unfolding.
The target was the inner mitochondrial membrane.
This detail gave SS-31 its identity. The inner mitochondrial membrane is the folded surface where oxidative phosphorylation occurs. It is where electron transport chain complexes operate, where the proton gradient is built, and where ATP synthase produces the energy currency of the cell. To reach that membrane is to reach the engine room of cellular life.
At first, the story was often framed around oxidative stress. Mitochondria can generate reactive oxygen species, especially under stress conditions such as ischemia-reperfusion injury. If SS-31 could reduce oxidative damage inside mitochondria, then it might help protect tissues when energy production became unstable. This was already important, especially for heart, kidney, brain, and muscle research.
But the deeper discovery was still unfolding.
As researchers studied SS-31 more closely, the mechanism began to shift from a simple antioxidant story toward a membrane architecture story. The peptide appeared to interact with cardiolipin, the specialized lipid concentrated in the inner mitochondrial membrane. Cardiolipin is not just another fat molecule. It helps maintain cristae structure and supports the organization of electron transport chain complexes. Without properly remodeled cardiolipin, the mitochondrial power grid loses stability.
This made SS-31 different from a typical antioxidant.
A typical antioxidant might be imagined as cleaning up sparks after the wiring has begun to fail. SS-31 seemed to act closer to the wiring itself. By associating with cardiolipin-rich membrane environments, it was being studied as a way to help stabilize the structure where electron flow, ATP production, and oxidative stress are linked.
That is the central discovery of the SS-31 story.
The peptide did not merely target mitochondria as a vague destination. It reached the inner mitochondrial membrane, the precise landscape where energy production depends on lipid organization and structural order. Its small size was not a weakness. It was part of what allowed the peptide to travel, enter, and associate with one of the most important membranes in the cell.
This discovery changed the questions researchers could ask.
Could mitochondrial injury be treated at the level of membrane architecture? Could cardiolipin-rich structures be protected before energy failure became irreversible? Could a small peptide help preserve the organization of cristae, reduce electron leak, and support ATP production under stress? Could diseases rooted in mitochondrial membrane dysfunction be approached not only through genes, enzymes, or antioxidants, but through the physical environment where the energy machinery sits?
These questions turned SS-31 into more than a molecule.
They turned it into a new way of thinking about mitochondrial medicine.
The discovery was not simply that SS-31 existed. It was that a four-amino-acid peptide could reach the inner membrane of mitochondria and become part of the scientific conversation about how cells protect their power grid.
In that sense, SS-31 did not begin as a cure.
It began as a key — small enough to travel, chemically unusual enough to reach the right place, and powerful enough to open a new door into the biology of energy failure.
SS-31’s journey began with oxidative stress, but it did not stay there.
In the early years, the peptide was often described as a mitochondria-targeted antioxidant. That description made sense. Mitochondria are deeply connected to reactive oxygen species, especially when cells are under stress. When oxygen supply is interrupted and then restored, when electron flow becomes unstable, or when mitochondrial membranes lose their organization, reactive oxygen species can rise sharply. These molecules can damage proteins, lipids, DNA, and the mitochondria themselves.
For researchers studying ischemia-reperfusion injury, this was a major problem.
When blood flow is cut off, tissue is starved of oxygen. When blood flow returns, the sudden reintroduction of oxygen can paradoxically create a wave of mitochondrial stress. The mitochondrion, which normally uses oxygen to help produce energy, can become a source of injury. Electrons leak. Reactive oxygen species increase. Membranes swell. Cell-death pathways can begin. The return of oxygen, which should rescue the tissue, can also help damage it.
SS-31 appeared useful because it could reach mitochondria during this vulnerable moment.
Early studies showed that SS peptides could protect against mitochondrial swelling, oxidative cell death, and reperfusion injury. This gave SS-31 its first medical identity: a small peptide that might protect cells when mitochondrial stress was high. In this early chapter, the story was focused on oxidative damage. SS-31 was viewed as a way to reduce the sparks coming from an overloaded energy system.
But as the research matured, a more precise story emerged.
The real breakthrough was not just that SS-31 could reduce oxidative stress. It was that SS-31 seemed to associate with the inner mitochondrial membrane, especially with cardiolipin-rich environments. Cardiolipin became the key to understanding why this tiny peptide mattered.
Cardiolipin is one of the most important lipids in mitochondrial biology. It is found mainly in the inner mitochondrial membrane, where it helps shape cristae and organize the protein complexes involved in oxidative phosphorylation. These complexes do not operate in empty space. They depend on the membrane around them. Cardiolipin helps hold that environment together, supporting the structure and efficiency of the mitochondrial power grid.
When cardiolipin is healthy and properly remodeled, the energy machinery has a stable home.
When cardiolipin is damaged, oxidized, or poorly remodeled, the system can begin to unravel.
The electron transport chain becomes less efficient. Cristae structure can become abnormal. Electron leak may increase. Reactive oxygen species can rise. ATP production can weaken. The mitochondrion does not simply “run low on energy”; it loses the architecture that allows energy production to happen cleanly.
This changed the way researchers understood SS-31.
Instead of imagining it only as a cleanup crew for oxidative stress, scientists began to see it as a membrane-active peptide. SS-31 could bind lipid bilayers and influence membrane surface properties. It could interact with cardiolipin-associated environments. It could become part of the physical chemistry of the inner mitochondrial membrane. That made it less like a sponge for damage and more like a stabilizer for the place where damage begins.
This is the turning point of the SS-31 biography.
The story moved from antioxidant to architecture.
That movement matters because antioxidants alone have often struggled in clinical medicine. Oxidative stress is real, but it is often downstream of deeper dysfunction. If a power plant is sparking because its wiring is unstable, sweeping up sparks may not be enough. The wiring has to be protected. The structure has to be stabilized. The system has to be organized so energy can move properly.
SS-31 offered that possibility.
Its small size allowed it to enter cells. Its chemical structure allowed it to associate with mitochondrial membranes. Its relationship with cardiolipin gave it a more specific role in the inner mitochondrial membrane. The peptide became a tool for asking whether mitochondrial dysfunction could be treated not only by changing genes, enzymes, or fuel supply, but by protecting the lipid architecture that supports the energy system itself.
That idea opened many research paths.
In the heart, researchers studied elamipretide because cardiomyocytes are packed with mitochondria and depend on constant ATP production. In the kidney, SS-31 was explored in models where mitochondrial stress contributes to injury. In the eye, the retina’s extreme energy demand made mitochondrial protection attractive. In primary mitochondrial myopathy, researchers tested whether a peptide aimed at mitochondrial membranes could improve walking and fatigue in patients with inherited mitochondrial disease.
The results were mixed.
This is important. SS-31 did not become a universal solution simply because its mechanism was elegant. Some trials did not meet their primary endpoints. Heart failure studies did not produce the clear improvements researchers hoped for. A broad Phase 3 trial in primary mitochondrial myopathy did not show significant improvement in six-minute walk distance or fatigue at 24 weeks compared with placebo. These disappointments are part of the real journey.
They also taught the field something important.
Mitochondrial disease is not one disease. It is a category of problems with many genetic causes, tissue patterns, ages of onset, severities, and compensatory mechanisms. A therapy that helps protect the inner mitochondrial membrane may matter greatly in one biological context and not enough in another. The target may be real, but the match between target and disease must be precise.
That is why Barth syndrome became so important.
Barth syndrome is not simply a disease where mitochondria are stressed. It is a disease where cardiolipin remodeling is directly disrupted. The TAZ gene is involved in remodeling cardiolipin, and when that process is impaired, the inner mitochondrial membrane loses part of the lipid organization it needs. For SS-31, this was not just another mitochondrial condition. It was a disease connected to the very membrane biology that the peptide was built to support.
In that moment, the journey came into focus.
SS-31 began as a mitochondria-targeted peptide antioxidant. It evolved into a cardiolipin-binding, membrane-stabilizing candidate. It moved through broad mitochondrial stress research, met clinical disappointment in some larger disease settings, and found its most coherent biological fit in Barth syndrome, where cardiolipin was not a side character but the center of the disease.
This is the deeper lesson of the journey.
The future of mitochondrial medicine may not come from treating all mitochondrial dysfunction the same way. It may come from matching the therapy to the precise failure point. If the problem is genetic, the answer may need to be genetic. If the problem is enzymatic, the answer may need to be enzymatic. If the problem is membrane architecture, then a membrane-targeted peptide like SS-31 becomes a much more meaningful idea.
SS-31’s journey therefore tells a story of refinement.
At first, researchers saw a peptide that could protect mitochondria from oxidative stress. Then they saw a peptide that could reach the inner membrane. Then they saw cardiolipin. Then they saw that clinical success would depend not only on mitochondrial targeting, but on choosing the right disease, the right endpoint, and the right biological context.
The peptide did not promise to fix every power failure.
It taught researchers to look more closely at the power grid itself.
The legacy of SS-31 is not that it solved mitochondrial disease.
It did something more complicated and, in some ways, more important. It showed that mitochondrial medicine could be aimed at structure, not just chemistry. It gave researchers a way to think about the inner mitochondrial membrane as a therapeutic landscape — a place where damage begins, where energy production depends on order, and where a tiny peptide might help preserve the architecture that keeps the system alive.
For decades, mitochondria had been studied as engines of energy production. Scientists understood the electron transport chain, ATP synthesis, membrane potential, reactive oxygen species, and the role of mitochondrial failure in disease. But turning that knowledge into medicine proved difficult. Mitochondria are protected, complex, and deeply connected to nearly every part of cellular life. To influence them safely, a therapy has to reach the right place without disturbing too much else.
SS-31 became important because it offered a different kind of approach.
It was not a replacement enzyme. It was not a gene correction. It was not a fuel. It was not a broad stimulant demanding more output from a struggling cell. Instead, SS-31 was built around access and protection. It could enter cells, associate with mitochondria, and interact with the inner membrane environment where cardiolipin helps organize the machinery of energy production.
That made the peptide a bridge between mechanism and medicine.
The early mechanism was elegant: reach mitochondria, reduce oxidative injury, protect the inner membrane. The deeper mechanism became even more compelling: interact with cardiolipin-rich membrane environments and help stabilize the lipid architecture that supports cristae, electron flow, and ATP production. But medicine does not live on elegant mechanisms alone. A therapy must prove that its mechanism can change outcomes in real people.
That is where the story became difficult.
Elamipretide moved through several clinical research programs because mitochondrial dysfunction appears in many diseases. Heart failure seemed logical because the heart is one of the most energy-demanding organs in the body. Primary mitochondrial myopathy seemed logical because inherited mitochondrial disorders directly affect energy metabolism and muscle function. Eye disease seemed logical because the retina has enormous metabolic demand. Barth syndrome seemed logical because the disease is rooted in cardiolipin remodeling failure.
But logic is not the same as success.
Some trials disappointed. In heart failure, the hoped-for improvement in cardiac structure or function did not clearly emerge. In primary mitochondrial myopathy, a broad Phase 3 trial did not meet its primary endpoints for walking distance or fatigue. These results are essential to the legacy because they prevent the story from becoming too easy. SS-31 was not a magic key that opened every mitochondrial door.
Instead, the disappointments sharpened the lesson.
Mitochondrial dysfunction is not one target. It is a pattern that can arise from many causes. Two patients may both have impaired energy production, but the source of that impairment may be completely different. One may have a defect in mitochondrial DNA. Another may have a problem in nuclear-encoded mitochondrial proteins. Another may have secondary mitochondrial stress caused by inflammation, ischemia, aging, or tissue injury. A peptide that stabilizes the inner membrane may matter greatly in one setting and not enough in another.
This is why Barth syndrome became the defining chapter.
In Barth syndrome, the connection was unusually direct. The disease involves defects in tafazzin biology, which disrupts cardiolipin remodeling. Cardiolipin is not a background detail in Barth syndrome. It is part of the disease’s center. If SS-31’s strongest scientific identity was tied to cardiolipin-rich mitochondrial membranes, then Barth syndrome offered one of the clearest biological matches.
Here, the story became personal.
Barth syndrome is ultra-rare, serious, and life-limiting. It can affect the heart, skeletal muscle, growth, endurance, immune function, and daily energy. For families living with the disease, mitochondrial dysfunction is not a textbook mechanism. It is fatigue. It is weakness. It is uncertainty. It is a child who tires too easily, a body that struggles to keep up, and a future shaped by a disease most people have never heard of.
That human reality changed the meaning of the research.
For patients and families, elamipretide was not merely a cardiolipin-interacting tetrapeptide. It was a possible treatment in a disease with no approved therapy. It represented time, strength, walking, function, and hope. The clinical endpoints mattered, but so did the lived experience behind them. In ultra-rare disease, the distance between a data point and a family’s daily life can be very small.
This is where SS-31 entered the public and regulatory arena.
The path to approval was not simple. Evidence was debated. Trial size was limited by the rarity of the disease. Regulators had to decide whether observed changes were reasonably likely to predict meaningful benefit. Patient advocates argued from the reality of urgent need. Scientists and reviewers weighed uncertainty. The company carried the burden of trying to develop a drug for a tiny population where conventional large trials were nearly impossible.
In 2025, elamipretide, under the name Forzinity, received accelerated approval as the first treatment for Barth syndrome in eligible patients. That approval became a major milestone in mitochondrial medicine. It did not mean every question was answered. Accelerated approval still requires confirmatory evidence. Debate remained around the strength of the data, the choice of endpoints, cost, and access. But the milestone mattered.
For the first time, a therapy built around this mitochondrial membrane-protection concept had crossed into approved medicine for Barth syndrome.
That is SS-31’s legacy.
It showed that mitochondrial medicine could move beyond theory, but it also showed how hard that movement is. It showed that targeting the inner membrane may be powerful, but not universal. It showed that cardiolipin biology can be more than a mechanism in a diagram; in the right disease, it can become the reason a therapy makes sense. It showed that rare-disease medicine depends not only on molecular science, but on trial design, patient advocacy, regulatory judgment, and society’s willingness to confront uncertainty.
The legacy of SS-31 is therefore not a straight line from discovery to cure.
It is a story of refinement.
A peptide first understood as a mitochondrial antioxidant became a membrane-stabilizing molecule. A broad mitochondrial idea became a cardiolipin-centered mechanism. A platform tested across many diseases found its clearest home in an ultra-rare disorder. A scientific hypothesis became a regulatory debate. A four-amino-acid peptide became a symbol of how difficult, and how meaningful, mitochondrial medicine can be.
SS-31’s legacy is that it taught researchers to look at the mitochondrion differently.
Not only as a source of energy.
Not only as a source of damage.
But as a structure whose architecture can fail — and whose architecture may one day be protected.
The next chapter of SS-31 begins with a difficult question.
How much evidence is enough when the disease is devastating, the science is compelling, and the patient population is almost too small for traditional trials?
This is not a simple question. In common diseases, medicine can often rely on large clinical trials, thousands of patients, repeated studies, and statistically powerful endpoints. Ultra-rare diseases do not always allow that luxury. There may be only a small number of patients available. Symptoms may vary. Disease progression may be uneven. A clinical change that matters deeply to a patient may be hard to capture in a conventional endpoint.
Barth syndrome placed SS-31 directly inside that challenge.
The biology made sense. Barth syndrome involves defective cardiolipin remodeling, and SS-31 was built around the idea of protecting cardiolipin-rich mitochondrial membranes. Few disease matches could be more thematically aligned. A peptide designed to support the inner mitochondrial membrane was being tested in a disease where the inner mitochondrial membrane’s lipid architecture was impaired.
But regulatory medicine cannot approve a therapy on biological elegance alone.
It needs evidence. It needs outcomes. It needs to know whether a treatment changes something meaningful, whether the benefit outweighs the risk, and whether the observed signal is strong enough to justify access. In ultra-rare disease, those questions become unusually hard. Waiting for perfect evidence may mean waiting too long. Moving too quickly may mean approving a therapy before its true benefit is fully understood.
That tension shaped the public story of elamipretide.
Families living with Barth syndrome saw more than a trial design. They saw a possible treatment where none existed before. They saw children and adults facing fatigue, weakness, cardiac risk, and limited options. For them, the question was not abstract. It was not only about statistical certainty. It was about time, function, and hope.
Regulators saw a different responsibility.
They had to protect the standard of evidence. They had to ask whether improvements in muscle strength were likely to predict real clinical benefit. They had to consider whether the available data were persuasive enough, whether uncertainties were acceptable, and whether confirmatory evidence would eventually answer the remaining questions. In this way, SS-31 became more than a mitochondrial peptide. It became a case study in how modern medicine handles uncertainty.
The future of SS-31 will likely be shaped by that balance.
Its approval in Barth syndrome does not mean the peptide has proven itself across all mitochondrial diseases. It does not erase the failed or disappointing trials in broader conditions. It does not mean every disease involving mitochondrial stress will respond in the same way. The future will require more precision, not less.
That precision may come from genetics.
Mitochondrial diseases are not interchangeable. A therapy that supports cardiolipin biology may be most meaningful when cardiolipin dysfunction is central to the disease. A therapy that stabilizes membrane architecture may work best where membrane architecture is a primary point of failure. Future research may need to identify which patient groups are biologically matched to elamipretide’s mechanism, rather than assuming that all mitochondrial dysfunction will respond equally.
This is one of the most important lessons of SS-31.
The future of mitochondrial medicine may not be built around one universal mitochondrial drug. It may be built around matching therapies to specific failure patterns: cardiolipin remodeling, electron transport chain defects, mitochondrial DNA maintenance, oxidative stress vulnerability, cristae instability, or tissue-specific energy collapse. SS-31 helped point the field toward that more precise future.
There is also a future in measurement.
Mitochondrial disease can be difficult to measure because energy failure affects the body in many ways. Walking distance, fatigue scores, muscle strength, cardiac function, biomarkers, patient-reported outcomes, and daily endurance may all tell part of the story. But no single measure captures everything. For rare diseases, researchers may need smarter endpoints that reflect what patients actually experience while still satisfying scientific and regulatory standards.
This is where the SS-31 story becomes deeply human.
A small increase in strength may look modest on paper. But for a patient, it may mean climbing stairs, walking farther, standing longer, or participating in daily life with less exhaustion. The challenge is translating that lived meaning into evidence strong enough to guide medicine. The future of ultra-rare disease therapy may depend on learning how to measure what matters without lowering the bar so far that uncertainty replaces proof.
SS-31 also points toward a broader future in mitochondrial aging and high-energy tissues.
Researchers remain interested in mitochondrial protection across heart, muscle, retina, kidney, brain, and metabolic disease. The reason is understandable. Mitochondria sit at the center of cellular resilience. When they fail, many tissues suffer. But the history of elamipretide teaches caution. The phrase “mitochondrial support” is not enough. Future studies will need to ask sharper questions: which tissue, which disease, which mechanism, which patients, which endpoint, and which level of evidence?
The most exciting future is not hype.
It is specificity.
SS-31’s next chapter is not about promising energy for everyone. It is about understanding when the inner mitochondrial membrane is truly the right therapeutic target. It is about identifying the diseases where cardiolipin biology is central enough that stabilizing the membrane might change outcomes. It is about designing trials that can work in rare populations without abandoning scientific rigor. It is about making mitochondrial medicine precise enough to be trusted.
The approval of Forzinity for Barth syndrome may be remembered as a beginning, not an ending.
It opened a door for a new class of thinking: mitochondrial-targeted medicine aimed not only at enzymes or genes, but at the membrane architecture that makes energy production possible. It also opened a debate about cost, access, evidence, and the responsibility of medicine to patients with diseases too rare to fit comfortably into conventional systems.
That is the future SS-31 leaves us with.
A four-amino-acid peptide reached the inner mitochondrial membrane. It followed cardiolipin into the folded power grid of the cell. It moved through hope, disappointment, rare disease, regulatory debate, and eventual approval. It showed that mitochondrial medicine is possible, but not easy.
The next chapter will ask whether that possibility can become more precise, more measurable, more accessible, and more trusted.
Not by pretending that every power failure is the same.
But by learning exactly where the grid is broken — and whether a tiny peptide can help hold it together.
Cell-Permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane Inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury
Kesheng Zhao, Guo-Min Zhao, Dunli Wu, Yi Soong, Alex V. Birk, Peter W. Schiller, and Hazel H. Szeto. 2004. Journal of Biological Chemistry.
Link: https://pubmed.ncbi.nlm.nih.gov/15178689/
Full text / journal page: https://www.jbc.org/article/S0021-9258(20)77302-3/fulltext
This paper is one of the foundational sources for the SS-31 story. It showed that Szeto–Schiller peptides could enter cells, target the inner mitochondrial membrane, and protect against mitochondrial swelling, oxidative cell death, and reperfusion injury. This is the point where SS-31 begins to look different from an ordinary antioxidant: it was not simply acting broadly in the cell, but reaching the mitochondrial membrane where energy failure and oxidative injury begin.
Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants
Hazel H. Szeto. 2006. The AAPS Journal.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3231562/
This review lays out the early logic of the Szeto–Schiller peptide family. It describes these peptides as cell-permeable and mitochondria-targeted, with the ability to reduce mitochondrial reactive oxygen species, inhibit mitochondrial permeability transition, prevent cytochrome c release, and protect against oxidant-induced cell death. It is useful for explaining how SS-31 was first understood as a mitochondria-targeted cytoprotective peptide.
Mitochondria-Targeted Cytoprotective Peptides for Ischemia–Reperfusion Injury
Hazel H. Szeto. 2008. Antioxidants & Redox Signaling.
Link: https://pubmed.ncbi.nlm.nih.gov/17999629/
This paper frames SS-31’s early medical direction. Ischemia–reperfusion injury occurs when tissue loses blood flow and then suffers oxidative damage when blood flow returns. SS-31 became interesting because it appeared to protect mitochondria during this vulnerable period, especially by helping reduce injury tied to oxidative stress and mitochondrial permeability transition.
Methods for Preventing Mitochondrial Permeability Transition
Patent: US7576061B2
Link: https://patents.google.com/patent/US7576061B2/en
This patent record is central to the SS-31 development story. It describes methods of reducing or preventing mitochondrial permeability transition using aromatic-cationic peptides. This supports the early development concept that SS peptides could protect mitochondria from a major failure event associated with swelling, cytochrome c release, and cell death.
Methods for Preventing Mitochondrial Permeability Transition
Patent application family: WO2004070054A2
Link: https://patents.google.com/patent/WO2004070054A2/en
This patent application is part of the early SS peptide protection platform. It helps show that the invention was not framed around one narrow disease, but around protecting mitochondria from permeability transition — a common pathway in severe mitochondrial stress.
Methods of Treating or Preventing Aneurysm with SS-31
Patent: EP3771467A1
Link: https://patents.google.com/patent/EP3771467A1/en
This patent application shows how SS-31 became a platform concept beyond rare mitochondrial disease. It explores SS-31 in the context of aneurysm prevention or treatment, reinforcing the idea that mitochondrial membrane protection was viewed as relevant across multiple tissue-injury settings.
Methods and Compositions for Treating Burn-Related Hypermetabolism and Mitochondrial Dysfunction
Patent: EP2408463B1
Link: https://patents.google.com/patent/EP2408463B1/en
This patent adds another disease-context example. It supports the broader story that once researchers believed SS-31 could protect mitochondrial function, they explored applications in many conditions where mitochondrial stress contributes to tissue damage.
2004 — SS-31 is shown to target the inner mitochondrial membrane.
Primary paper: https://pubmed.ncbi.nlm.nih.gov/15178689/
The 2004 Journal of Biological Chemistry paper showed that cell-permeable peptide antioxidants could target the inner mitochondrial membrane and inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. This is the scientific starting point for SS-31 as a mitochondria-targeted peptide.
2006 — Hazel Szeto frames the SS peptide family as mitochondrial cytoprotective peptides.
Review link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3231562/
This review helped define the early mechanism: SS peptides could concentrate in mitochondria, reduce mitochondrial reactive oxygen species, inhibit permeability transition, and prevent cell-death pathways tied to mitochondrial failure.
2008 — SS-31 is connected to ischemia–reperfusion injury.
Review link: https://pubmed.ncbi.nlm.nih.gov/17999629/
This milestone matters because ischemia–reperfusion injury is one of the clearest situations where mitochondria become both necessary and dangerous. When oxygen returns after deprivation, mitochondria can generate damaging oxidative stress. SS-31 became part of the search for ways to protect mitochondria during that transition.
2013 — SS-31 is shown to re-energize ischemic mitochondria by interacting with cardiolipin.
The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin
A. V. Birk and colleagues. 2013. Journal of the American Society of Nephrology.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC3736700/
This paper is one of the most important mechanism milestones. It connects SS-31 to cardiolipin, the specialized lipid found in the inner mitochondrial membrane. This is where the story begins moving beyond “mitochondrial antioxidant” toward “cardiolipin and membrane architecture.”
2020 — SS-31’s mitochondrial interaction landscape is mapped.
Mitochondrial Protein Interaction Landscape of SS-31
J. D. Chavez and colleagues. 2020. Proceedings of the National Academy of Sciences.
Link: https://www.pnas.org/doi/10.1073/pnas.2002250117
PMC link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/
This paper explores SS-31’s interactions inside mitochondria. It is useful because it shows the field trying to understand SS-31 beyond a simple antioxidant explanation. The paper reinforces that SS-31 interacts with mitochondrial systems connected to cardiolipin-rich inner membrane biology.
2020 — SS-31 is shown to bind lipid bilayers and modulate membrane surface electrostatics.
The Mitochondria-Targeted Peptide SS-31 Binds Lipid Bilayers and Modulates Surface Electrostatics as a Key Component of Its Mechanism of Action
William Mitchell and colleagues. 2020. Journal of Biological Chemistry.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7247319/
This is a major mechanistic paper. It supports the idea that SS-31 acts through membrane physical chemistry, not only through direct antioxidant scavenging. This is important for the biography because it lets us describe SS-31 as a peptide that helps stabilize the environment where mitochondrial energy production happens.
2021 — Barth syndrome TAZPOWER trial and open-label extension data are published.
A Phase 2/3 Randomized Clinical Trial Followed by an Open-Label Extension to Evaluate Elamipretide in Barth Syndrome
C. M. Thompson and colleagues. 2021. Genetics in Medicine.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/
This study is central to the Barth syndrome chapter. Barth syndrome is caused by defects in tafazzin biology that disrupt cardiolipin remodeling. Because elamipretide targets cardiolipin-associated mitochondrial structure and function, Barth syndrome became one of the most scientifically coherent disease targets for SS-31.
2023 — Primary mitochondrial myopathy Phase 3 trial does not meet primary endpoints.
Safety, Tolerability, and Efficacy of Elamipretide in Primary Mitochondrial Myopathy: A Randomized Clinical Trial
MMPOWER-3 investigators. 2023. Neurology.
Link: https://pubmed.ncbi.nlm.nih.gov/37268435/
This is an important honesty point. The trial found that elamipretide did not improve the six-minute walk test or fatigue at 24 weeks compared with placebo in a genetically diverse primary mitochondrial myopathy population. This result keeps the article balanced: SS-31 has a compelling mechanism, but mitochondrial disease is complex, and broad clinical translation has not been simple.
2024 — Long-term Barth syndrome extension data report 168-week outcomes.
Long-Term Elamipretide in Barth Syndrome: 168-Week Open-Label Extension Results
PubMed link: https://pubmed.ncbi.nlm.nih.gov/38602181/
Barth Syndrome Foundation summary: https://www.barthsyndrome.org/barthsyndrome/familyresources/research-summaries/168-week-open-label-extension-results-of-tazpower.html
This milestone is useful for the Legacy section because it adds long-term disease-specific context. The Barth Syndrome Foundation summary is also valuable as a patient-facing explanation of why the data mattered to families and the rare-disease community.
2024 — FDA advisory committee publicly reviews elamipretide for Barth syndrome.
FDA meeting page: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-10-2024-meeting-cardiovascular-and-renal-drugs-advisory-committee-10102024
YouTube meeting record: https://www.youtube.com/watch?v=guVE0UilHkY
This public advisory committee meeting is one of the most important public-event sources for the biography. It captures the regulatory debate, scientific uncertainty, patient urgency, and rare-disease evidence challenge around elamipretide.
2025 — FDA grants accelerated approval to Forzinity for Barth syndrome.
FDA announcement: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
FDA approval letter: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000Approv.pdf
Stealth BioTherapeutics announcement: https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome/
This is the regulatory turning point. Forzinity, elamipretide injection, became the first FDA-approved treatment for Barth syndrome in patients weighing at least 30 kg. This milestone makes SS-31 a landmark story in mitochondrial medicine and rare-disease drug development.
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
C. Tung and colleagues. 2025.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
PubMed link: https://pubmed.ncbi.nlm.nih.gov/39940712/
This is one of the best current overview sources. It summarizes elamipretide’s structure, mitochondrial targeting, cardiolipin binding, cristae stabilization, oxidative stress reduction, and therapeutic research directions. This should be one of the main sources for the mechanism section.
The Mitochondria-Targeted Peptide SS-31 Binds Lipid Bilayers and Modulates Surface Electrostatics as a Key Component of Its Mechanism of Action
William Mitchell and colleagues. 2020. Journal of Biological Chemistry.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7247319/
This mechanistic paper helps explain SS-31 as a membrane-active peptide. It gives us the language for describing SS-31 as acting at the level of lipid bilayers, membrane surface charge, and mitochondrial architecture.
Mitochondrial Protein Interaction Landscape of SS-31
J. D. Chavez and colleagues. 2020. PNAS.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/
Publisher link: https://www.pnas.org/doi/10.1073/pnas.2002250117
This paper adds depth to the mechanism story by mapping SS-31’s mitochondrial interaction landscape. It supports a more sophisticated explanation of SS-31’s activity inside mitochondria.
SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease
Y. Zhu and colleagues. 2022.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202/
This review is useful for showing how SS-31 became a broader research platform in mitochondrial stress biology. It summarizes SS-31 research in renal disease and discusses mitochondrial ROS, depolarization, permeability transition, and calcium-induced swelling.
Dry Age-Related Macular Degeneration and Elamipretide Research
ReCLAIM-2 / AMD paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11599447/
This source is important because the retina is highly energy-dependent and vulnerable to mitochondrial dysfunction. Elamipretide’s study in dry AMD and geographic atrophy shows how SS-31 research expanded beyond muscle and heart into eye disease.
Heart Failure Research: PROGRESS-HF
Effects of Elamipretide on Left Ventricular Function in Patients with Heart Failure with Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
Link: https://pubmed.ncbi.nlm.nih.gov/32068002/
This study is important because heart muscle depends heavily on mitochondria, making heart failure a logical target. However, the trial did not show improvement in the primary cardiac remodeling endpoint at 4 weeks compared with placebo. This should be included to keep the article honest.
Weill Cornell Medicine / Cornell University
Associated scientist: Hazel H. Szeto
Weill Cornell article: https://news.weill.cornell.edu/news/2025/12/the-winding-road-from-bench-to-fda-approval-for-first-mitochondria-targeting-drug
Foundational paper: https://pubmed.ncbi.nlm.nih.gov/15178689/
Weill Cornell is central to the SS-31 discovery story through Hazel Szeto’s work. This institution anchors the pharmacology and mitochondrial-targeting side of the biography.
Institut de recherches cliniques de Montréal / IRCM
Associated scientist: Peter W. Schiller
Peter W. Schiller profile: https://www.ircm.qc.ca/en/research/principal-investigators/peter-w-schiller
IRCM is central because Peter W. Schiller co-discovered SS-31/elamipretide with Hazel Szeto. Schiller gives the story its peptide-chemistry foundation.
Stealth BioTherapeutics / Mighty Therapeutics
Associated therapy: Elamipretide / Forzinity
Company science and pipeline page: https://stealthbt.com/science-pipeline/
FDA approval announcement: https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome/
Stealth BioTherapeutics is the clinical-development company behind elamipretide. The company moved SS-31 from academic mitochondrial biology into clinical trials and eventual accelerated approval for Barth syndrome.
Barth Syndrome Foundation
Associated focus: patient advocacy, education, research support, regulatory engagement
Main website: https://www.barthsyndrome.org/
FDA advisory committee advocacy page: https://www.barthsyndrome.org/advocacy/fdaadcomm.html
TAZPOWER extension summary: https://www.barthsyndrome.org/barthsyndrome/familyresources/research-summaries/168-week-open-label-extension-results-of-tazpower.html
The Barth Syndrome Foundation is important for the human side of the SS-31 story. It represents the patient and family community that helped make the regulatory debate visible. This source helps explain why elamipretide was more than a scientific project; it became a rare-disease access and evidence-standard issue.
U.S. Food and Drug Administration
Associated focus: advisory committee review, accelerated approval, post-marketing confirmatory trial
FDA advisory committee meeting: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-10-2024-meeting-cardiovascular-and-renal-drugs-advisory-committee-10102024
FDA approval announcement: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
FDA approval letter: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000Approv.pdf
The FDA is central to the Next Chapter because Forzinity’s approval was scientifically meaningful and publicly debated. The accelerated approval pathway, advisory committee documents, reviewer disagreement, and required confirmatory trial are part of the modern SS-31 story.
Johns Hopkins Medicine / Johns Hopkins University
Associated focus: Barth syndrome clinical trial participation and patient story
Johns Hopkins article: https://hub.jhu.edu/2025/09/25/fda-approves-barth-syndrome-treatment/
This source adds a patient-centered and clinical-site perspective. It is useful for bringing the story back to people: walking, fatigue, daily function, and rare-disease families.
FDA Cardiovascular and Renal Drugs Advisory Committee Meeting — October 10, 2024
FDA meeting page: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-10-2024-meeting-cardiovascular-and-renal-drugs-advisory-committee-10102024
YouTube webcast: https://www.youtube.com/watch?v=guVE0UilHkY
This is the best public-event source for SS-31/elamipretide. It includes the scientific, regulatory, company, and patient-advocacy context behind the Barth syndrome review.
FDA Grants Accelerated Approval to First Treatment for Barth Syndrome
FDA announcement: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
This is the official public regulatory milestone. It confirms Forzinity as the first approved treatment for Barth syndrome in eligible patients.
Reuters: FDA Asks Stealth BioTherapeutics to Resubmit Application for Rare Genetic Condition Therapy
This article documents the regulatory setback before approval, including the FDA request for resubmission and Stealth’s workforce reduction. It is useful for showing that the path to approval was difficult, not straightforward.
Reuters: FDA Approves First Treatment for Rare, Life-Threatening Disease in Males
This article covers the accelerated approval and summarizes the FDA’s rationale around knee muscle strength as a marker reasonably likely to predict clinical benefit.
Reuters: FDA Cleared Pricey Rare Disease Drug Over Reviewer Objections
This article is important for the Next Chapter because it explains the controversy around the approval, including reviewer objections, evidence concerns, cost, and post-marketing obligations.
The Guardian: Rare-Disease Families and FDA Evidence Debate
Link: https://www.theguardian.com/science/2025/jul/06/fda-drugs-ultra-rare-diseases
This article helps explain the emotional and ethical tension around ultra-rare disease drug approvals. It is useful background for discussing how families, regulators, and scientists weigh uncertainty when patient populations are extremely small.
Barth Syndrome Foundation: Elamipretide Media Coverage
Link: https://www.barthsyndrome.org/advocacy/elamipretide-media.html
This page collects media coverage and public updates related to elamipretide. It is a useful hub for tracking patient-facing developments and public discussion.
FORZINITY / Elamipretide — United Mitochondrial Disease Foundation
Link: https://umdf.org/forzinity-elamipretide/
This is a patient-facing explanation of Forzinity and Barth syndrome. It is useful for understanding how mitochondrial disease organizations explain elamipretide to families and patients.
DrugBank: Elamipretide
Link: https://go.drugbank.com/drugs/DB11846
This is a concise drug-development reference for elamipretide. It can be useful for checking naming, classification, and development identity.
ClinicalTrials.gov Search: Elamipretide
Link: https://clinicaltrials.gov/search?term=elamipretide
This search page is useful for reviewing the clinical-trial landscape across Barth syndrome, primary mitochondrial myopathy, heart failure, dry AMD, LHON, and other indications.
ClinicalTrials.gov Search: SS-31
Link: https://clinicaltrials.gov/search?term=SS-31
This search helps capture older or alternate naming around SS-31 and related clinical trials.
ClinicalTrials.gov Protocol: Elamipretide in Leber Hereditary Optic Neuropathy
Protocol PDF: https://cdn.clinicaltrials.gov/large-docs/19/NCT02693119/Prot_SAP_000.pdf
This is useful for the eye-disease branch of the SS-31 story. LHON is a mitochondrial optic nerve disease, making it a logical research area for mitochondrial-targeted therapy.
CureFA: Elamipretide
Link: https://www.curefa.org/drug-development/elamipretide/
This source explains elamipretide in a patient-facing research-development style, especially in relation to cardiolipin and mitochondrial function. It is useful as a simpler explanation source, but primary journal and FDA sources should carry the factual weight.
Explore more peptide biographies and follow the stories behind the discoveries.
The Body Protection Compound That Defied Expectation
The Body Protection Compound That Defied Expectation
The Body Protection Compound That Defied Expectation
Ask Nova